CytomX Therapeutics (CTMX) Other Non-Current Assets (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Other Non-Current Assets data on file, last reported at $31000.0 in Q1 2026.

• Quarterly Other Non-Current Assets fell 96.98% year-over-year to $31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31000.0 (down 96.98% YoY) and the FY2025 annual result came in at $31000.0, down 96.98% from the prior year.
• Other Non-Current Assets was little changed at $31000.0 in Q1 2026, from $31000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q1 2025 to a low of $31000.0 in Q4 2025.
• A 5-year average of $796235.3 and a median of $917000.0 in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 1137.35% — and 2026, when it plunged 96.98%.
• Tracing CTMX's Other Non-Current Assets over 5 years: stood at $917000.0 in 2022, then slumped by 90.95% to $83000.0 in 2023, then soared by 1137.35% to $1.0 million in 2024, then slumped by 96.98% to $31000.0 in 2025, then changed by 0.0% to $31000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $31000.0 (Q1 2026), $31000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.